ARTA
CBMG

A.R.T. Advisors’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

A.R.T. Advisors’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,587
Closed -$110K – 1810
2017
Q2 		$110K Buy
+12,587
New +$111K 0.01% 1246
2015
Q3 		– Sell
-21,543
Closed -$808K – 1713
2015
Q2 		$808K Buy
+21,543
New +$695K 0.03% 809

Other funds holding CBMG

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

A.R.T. Advisors's CBMG Position: Q3 2017 in Review

A.R.T. Advisors sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2017, closing a stake of 12,587 shares — an estimated $110K sold.

A.R.T. Advisors first reported a position in CBMG in Q2 2015 and held it in 2 quarters. The position peaked at $808K in Q2 2015. 20 funds tracked by Wall St. Rank hold CBMG as of Q3 2017.

  • A.R.T. Advisors reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 12,587 Cellular Biomedicine Group, Inc. shares in Q3 2017, an estimated $110K.
  • A.R.T. Advisors first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 2 quarters.
  • A.R.T. Advisors's Cellular Biomedicine Group, Inc. position peaked at $808K in Q2 2015.
  • 20 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2017.

Based on A.R.T. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.